Head to head
Pramlintide against Amylin
The hormone and the drug built to replace it. Native human amylin aggregates into amyloid, which is why it could never be given as a medicine, and pramlintide exists because three amino acid substitutions stop that happening.
Column A
PramlintidePramlintide (amylin analogue)
The only amylin analogue ever approved for diabetes, and the FDA now lists every Symlin product as discontinued. Approved is not the same as available.
Column B
AmylinAmylin (islet amyloid polypeptide)
Co-released with insulin from the same beta cell, and the parent ligand of cagrilintide and CagriSema. Native human amylin clumps into amyloid, which is why it can never be a drug.
Side by side, on the facts we can check
| Attribute | Pramlintide | Amylin |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Approved as Symlin, but Drugs@FDA lists every Symlin product as Discontinued as of September 2026. Approved and marketed are different things and this is the gap between them. | Native amylin is not a drug. Its approved analogue pramlintide (Symlin) is listed as Discontinued in Drugs@FDA as of September 2026. Cagrilintide is investigational, in phase 3 combined with semaglutide. |
| Half-life | ~48 minutes | Native amylin is short-lived in circulation. For the approved analogue pramlintide the label gives roughly 48 minutes. |
| Molecular weight | 3,949.4 Da | Mature peptide is 37 amino acids, amidated, with one intramolecular disulfide. Precursor 9,806 Da (UniProt P10997). Pramlintide acetate is 3,949.4 Da per its FDA label. |
| Mechanism | Agonizes amylin receptors to delay gastric emptying, suppress post-meal glucagon, and promote satiety, complementing insulin. | Acts at amylin receptors, which are not dedicated receptors at all but the calcitonin receptor in complex with a receptor activity-modifying protein. RAMP1, RAMP2 or RAMP3 give AMY1, AMY2 and AMY3 respectively, and that accessory-protein mechanism is why amylin pharmacology overlaps with calcitonin. Physiologically it slows gastric emptying, suppresses postprandial glucagon and drives satiation via the area postrema. |
| Human studies cited | 4 | 2 |
| Legal status, US | FDA-approved, prescription only | Not a drug; endogenous hormone and research infusion peptide |
Frequently asked questions
What is the difference between Pramlintide and Amylin?
Pramlintide: The only amylin analogue ever approved for diabetes, and the FDA now lists every Symlin product as discontinued. Approved is not the same as available. Amylin: Co-released with insulin from the same beta cell, and the parent ligand of cagrilintide and CagriSema. Native human amylin clumps into amyloid, which is why it can never be a drug.
Which has stronger research evidence, Pramlintide or Amylin?
This database does not grade compounds. It counts what was run in people: 4 of the 4 studies cited on the Pramlintide profile were human work, against 2 of 3 for Amylin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Pramlintide and Amylin FDA-approved?
Pramlintide: Approved as Symlin, but Drugs@FDA lists every Symlin product as Discontinued as of September 2026. Approved and marketed are different things and this is the gap between them.. Amylin: Native amylin is not a drug. Its approved analogue pramlintide (Symlin) is listed as Discontinued in Drugs@FDA as of September 2026. Cagrilintide is investigational, in phase 3 combined with semaglutide..
Related posts
Blog articles that cover Pramlintide or Amylin, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.